RE-BVS – Piemonte Repository

Sfoglia per AUTORE
SU W
Collezione AOU San Luigi di Orbassano

Items : 6

5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death Ligand 1-Positive Advanced Non-Small-Cell Lung Cancer. in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer / J Thorac Oncol. 2021 May 25:S1556-0864(21)02172-9. doi: 10.1016/j.jtho.2021.05.001.

2021
AOU San Luigi di Orbassano

Herbst RS; Garon EB; Kim DW; Cho BC; Gervais R; Perez-Gracia JL; Han JY; Majem M; Forster MD; Monnet I; Novello S; Gubens MA; Boyer M; Su WC; Samkari A; Jensen EH; Kobie J; Piperdi B; Baas P;

Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study. in JTO clinical and research reports / JTO Clin Res Rep. 2020 Oct 26;2(2):100114. doi: 10.1016/j.jtocrr.2020.100114. eCollection 2021 Feb.

2021
AOU San Luigi di Orbassano

Yang JC; Reckamp KL; Kim YC; Novello S; Smit EF; Lee JS; Su WC; Akerley WL; Blakely CM; Groen HJM; Bazhenova L; Carcereny Costa E; Chiari R; Hsia TC; Golsorkhi T; Despain D; Shih D; Popat S; Wakelee H;

FP13.01 5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel in Previously Treated, PD-L1–Positive Advanced NSCLC in Journal of Thoracic Oncology

2021
AOU San Luigi di Orbassano

Herbst R; Garon E; Kim D; Cho BC; Gervais R; Perez-Gracia JL; Han J; Majem M; Forster MD; Monnet I; Novello S; Gubens MA; Boyer M; Su W; Samkari A; Jensen EH; Piperdi B; Baas P;

Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1?Positive, Advanced Non?Small-Cell Lung Cancer in the KEYNOTE-010 Study. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2020 May 10;38(14):1580-1590. doi: 10.1200/JCO.19.02446. Epub 2020 Feb 20.

2020
AOU San Luigi di Orbassano

Gubens MA; Su WC; Szalai Z; Novello S; Monnet I; Forster MD; Majem M; Arvis CD; Han JY; Perez-Gracia JL; Cho BC; Kim DW; Garon EB; Herbst RS; Ceresoli GL; Samkari A; Jensen EH; Lubiniecki GM; Baas P;

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. in Lancet (London, England) / Lancet. 2017 Nov 18;390(10109):2266-2277. doi: 10.1016/S0140-6736(17)32365-6. Epub 2017 Sep 12.

2017
AOU San Luigi di Orbassano

Petrylak DP; de Wit R; Chi KN; Drakaki A; Sternberg CN; Nishiyama H; Castellano D; Hussain S; Fléchon A; Bamias A; Yu EY; van der Heijden MS; Matsubara N; Alekseev B; Necchi A; Géczi L; Ou YC; Coskun HS; Su WP; Hegemann M; Percent IJ; Lee JL; Tucci M; Semenov A; Laestadius F; Peer A; Tortora G; Safina S; Del Muro XG; et alii...

Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer. in Investigational new drugs / Invest New Drugs. 2016 Oct;34(5):625-35. doi: 10.1007/s10637-016-0368-1. Epub 2016 Jun 27.

2016
AOU San Luigi di Orbassano

Scagliotti G; Kang JH; Smith D; Rosenberg R; Park K; Kim SW; Su WC; Boyd TE; Richards DA; Novello S; Hynes SM; Myrand SP; Lin J; Smyth EN; Wijayawardana S; Lin AB; Pinder-Schenck M;